nodes	percent_of_prediction	percent_of_DWPC	metapath
Clenbuterol—NGF—autonomic nervous system—conduct disorder	0.514	0.879	CbGeAlD
Clenbuterol—NGF—brain—conduct disorder	0.0497	0.085	CbGeAlD
Clenbuterol—ADRB3—Monoamine GPCRs—DRD4—conduct disorder	0.0196	0.0473	CbGpPWpGaD
Clenbuterol—ADRB3—Amine ligand-binding receptors—DRD4—conduct disorder	0.0165	0.0398	CbGpPWpGaD
Clenbuterol—TNF—Monoamine Transport—SLC6A4—conduct disorder	0.015	0.0363	CbGpPWpGaD
Clenbuterol—ADRB1—brain—conduct disorder	0.0129	0.0221	CbGeAlD
Clenbuterol—ADRB3—Monoamine GPCRs—HTR2A—conduct disorder	0.0128	0.0309	CbGpPWpGaD
Clenbuterol—ADRB3—G alpha (s) signalling events—CGA—conduct disorder	0.0121	0.0293	CbGpPWpGaD
Clenbuterol—ADRB1—Monoamine GPCRs—DRD4—conduct disorder	0.0116	0.0281	CbGpPWpGaD
Clenbuterol—NGF—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.0116	0.0281	CbGpPWpGaD
Clenbuterol—ADRB2—Monoamine GPCRs—DRD4—conduct disorder	0.0114	0.0275	CbGpPWpGaD
Clenbuterol—ADRB3—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0108	0.0259	CbGpPWpGaD
Clenbuterol—ADRB1—Melatonin metabolism and effects—MAOA—conduct disorder	0.0103	0.0249	CbGpPWpGaD
Clenbuterol—CYP1A2—Methylation—COMT—conduct disorder	0.0101	0.0244	CbGpPWpGaD
Clenbuterol—CYP1A1—Estrogen metabolism—COMT—conduct disorder	0.00992	0.0239	CbGpPWpGaD
Clenbuterol—ADRB1—Amine ligand-binding receptors—DRD4—conduct disorder	0.00978	0.0236	CbGpPWpGaD
Clenbuterol—ADRB2—Amine ligand-binding receptors—DRD4—conduct disorder	0.00957	0.0231	CbGpPWpGaD
Clenbuterol—NGF—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00876	0.0211	CbGpPWpGaD
Clenbuterol—CYP1A1—brain—conduct disorder	0.00835	0.0143	CbGeAlD
Clenbuterol—ADRB1—Monoamine GPCRs—HTR2A—conduct disorder	0.00759	0.0183	CbGpPWpGaD
Clenbuterol—ADRB2—Monoamine GPCRs—HTR2A—conduct disorder	0.00743	0.0179	CbGpPWpGaD
Clenbuterol—ADRB1—G alpha (s) signalling events—CGA—conduct disorder	0.00721	0.0174	CbGpPWpGaD
Clenbuterol—NGF—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00714	0.0172	CbGpPWpGaD
Clenbuterol—ADRB2—G alpha (s) signalling events—CGA—conduct disorder	0.00705	0.017	CbGpPWpGaD
Clenbuterol—CYP1A1—Melatonin metabolism and effects—MAOA—conduct disorder	0.00672	0.0162	CbGpPWpGaD
Clenbuterol—CYP1A1—Oxidative Stress—MAOA—conduct disorder	0.00654	0.0158	CbGpPWpGaD
Clenbuterol—ADRB1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00638	0.0154	CbGpPWpGaD
Clenbuterol—CYP1A2—Estrogen metabolism—COMT—conduct disorder	0.00632	0.0152	CbGpPWpGaD
Clenbuterol—ADRB2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00625	0.0151	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00579	0.014	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Other—DRD4—conduct disorder	0.00506	0.0122	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—CGA—conduct disorder	0.00441	0.0106	CbGpPWpGaD
Clenbuterol—CYP1A2—Melatonin metabolism and effects—MAOA—conduct disorder	0.00429	0.0103	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.00424	0.0102	CbGpPWpGaD
Clenbuterol—ADRB3—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00378	0.00913	CbGpPWpGaD
Clenbuterol—NGF—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00378	0.00912	CbGpPWpGaD
Clenbuterol—TNF—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.00366	0.00882	CbGpPWpGaD
Clenbuterol—TNF—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.00366	0.00882	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00344	0.00829	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00336	0.00811	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Other—HTR2A—conduct disorder	0.0033	0.00796	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00324	0.00782	CbGpPWpGaD
Clenbuterol—TNF—TGF-beta Receptor Signaling—EP300—conduct disorder	0.00322	0.00776	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00319	0.00769	CbGpPWpGaD
Clenbuterol—CYP1A1—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00305	0.00735	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—CGA—conduct disorder	0.00262	0.00631	CbGpPWpGaD
Clenbuterol—TNF—Signaling events mediated by HDAC Class I—EP300—conduct disorder	0.00261	0.0063	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.0026	0.00627	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—CGA—conduct disorder	0.00258	0.00623	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—CGA—conduct disorder	0.00256	0.00617	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—CGA—conduct disorder	0.00249	0.00601	CbGpPWpGaD
Clenbuterol—ADRB3—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00247	0.00595	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—DRD4—conduct disorder	0.00247	0.00595	CbGpPWpGaD
Clenbuterol—TNF—Transcriptional regulation of white adipocyte differentiation—EP300—conduct disorder	0.00242	0.00584	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—CGA—conduct disorder	0.00226	0.00546	CbGpPWpGaD
Clenbuterol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00225	0.00542	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0022	0.0053	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00212	0.0051	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—WASF1—conduct disorder	0.00207	0.00499	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.00201	0.00484	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.00201	0.00484	CbGpPWpGaD
Clenbuterol—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00194	0.00468	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00192	0.00464	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00188	0.00454	CbGpPWpGaD
Clenbuterol—CYP1A2—Phase II conjugation—COMT—conduct disorder	0.00178	0.00428	CbGpPWpGaD
Clenbuterol—CYP1A1—Biological oxidations—COMT—conduct disorder	0.00163	0.00393	CbGpPWpGaD
Clenbuterol—CYP1A1—Biological oxidations—MAOA—conduct disorder	0.00162	0.0039	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—HTR2A—conduct disorder	0.00161	0.00388	CbGpPWpGaD
Clenbuterol—CYP1A1—Metapathway biotransformation—COMT—conduct disorder	0.00161	0.00388	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—CGA—conduct disorder	0.00148	0.00357	CbGpPWpGaD
Clenbuterol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00147	0.00353	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—DRD4—conduct disorder	0.00147	0.00353	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—DRD4—conduct disorder	0.00145	0.00349	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—CGA—conduct disorder	0.00145	0.00349	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00143	0.00346	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—DRD4—conduct disorder	0.00143	0.00346	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—DRD4—conduct disorder	0.0014	0.00336	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00139	0.00334	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00138	0.00332	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—CGA—conduct disorder	0.00134	0.00324	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—CGA—conduct disorder	0.00134	0.00322	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—CGA—conduct disorder	0.00131	0.00317	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.00128	0.00309	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.00128	0.00309	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—DRD4—conduct disorder	0.00127	0.00306	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00126	0.00303	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00123	0.00296	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.00117	0.00282	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—WASF1—conduct disorder	0.00107	0.00258	CbGpPWpGaD
Clenbuterol—CYP1A2—Biological oxidations—COMT—conduct disorder	0.00104	0.00251	CbGpPWpGaD
Clenbuterol—CYP1A2—Biological oxidations—MAOA—conduct disorder	0.00103	0.00249	CbGpPWpGaD
Clenbuterol—CYP1A2—Metapathway biotransformation—COMT—conduct disorder	0.00103	0.00247	CbGpPWpGaD
Clenbuterol—CYP1A1—PPARA activates gene expression—EP300—conduct disorder	0.001	0.00241	CbGpPWpGaD
Clenbuterol—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—conduct disorder	0.000978	0.00236	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—HTR2A—conduct disorder	0.000956	0.00231	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—HTR2A—conduct disorder	0.000944	0.00228	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—HTR2A—conduct disorder	0.000935	0.00226	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—HTR2A—conduct disorder	0.00091	0.0022	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000884	0.00213	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—DRD4—conduct disorder	0.000828	0.002	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—HTR2A—conduct disorder	0.000827	0.00199	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—DRD4—conduct disorder	0.00081	0.00195	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—CGA—conduct disorder	0.000793	0.00191	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—CGA—conduct disorder	0.000776	0.00187	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—DRD4—conduct disorder	0.000752	0.00181	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—DRD4—conduct disorder	0.000749	0.00181	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—DRD4—conduct disorder	0.000736	0.00177	CbGpPWpGaD
Clenbuterol—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—conduct disorder	0.000674	0.00163	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—WASF1—conduct disorder	0.000636	0.00153	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—WASF1—conduct disorder	0.000622	0.0015	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—CGA—conduct disorder	0.000618	0.00149	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—EP300—conduct disorder	0.000548	0.00132	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—HTR2A—conduct disorder	0.00054	0.0013	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—HTR2A—conduct disorder	0.000529	0.00127	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—EP300—conduct disorder	0.0005	0.00121	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—HTR2A—conduct disorder	0.000491	0.00118	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—HTR2A—conduct disorder	0.000488	0.00118	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—HTR2A—conduct disorder	0.00048	0.00116	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—DRD4—conduct disorder	0.000444	0.00107	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—DRD4—conduct disorder	0.000435	0.00105	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—CGA—conduct disorder	0.000394	0.000949	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—HTR2A—conduct disorder	0.00029	0.000699	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—HTR2A—conduct disorder	0.000284	0.000684	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—COMT—conduct disorder	0.000279	0.000672	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—MAOA—conduct disorder	0.000277	0.000667	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000268	0.000647	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—EP300—conduct disorder	0.000259	0.000624	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—COMT—conduct disorder	0.000178	0.000429	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—MAOA—conduct disorder	0.000176	0.000426	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000171	0.000413	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—EP300—conduct disorder	0.000154	0.00037	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—EP300—conduct disorder	0.00015	0.000362	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—EP300—conduct disorder	0.00012	0.000288	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—EP300—conduct disorder	7.62e-05	0.000184	CbGpPWpGaD
